• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Pancreatic Cancer - Pipeline Review, H2 2012 Product Image

Pancreatic Cancer - Pipeline Review, H2 2012

  • ID: 2335413
  • November 2012
  • 340 pages
  • Global Markets Direct

Pancreatic Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pancreatic Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pancreatic Cancer.
- A review of the Pancreatic Cancer products under development by companies and universities/research institutes READ MORE >

2
List of Tables 7
List of Figures 12
Introduction 13
REPORT COVERAGE 13
Pancreatic Cancer Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Pancreatic Cancer 15
Pancreatic Cancer Therapeutics under Development by Companies 17
Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes 30
Late Stage Products 43
Comparative Analysis 43
Mid Clinical Stage Products 44
Comparative Analysis 44
Early Clinical Stage Products 45
Comparative Analysis 45
Discovery and Pre-Clinical Stage Products 46
Comparative Analysis 46
Pancreatic Cancer Therapeutics – Products under Development by Companies 47
Pancreatic Cancer Therapeutics – Products under Investigation by Universities/Institutes 63
Companies Involved in Pancreatic Cancer Therapeutics Development 87
Bristol-Myers Squibb Company 87
Johnson & Johnson 88
F. Hoffmann-La Roche Ltd. 89
Amgen Inc. 90
Sanofi-Aventis 91
AstraZeneca PLC 92
Eli Lilly and Company 93
Viralytics Ltd. 94
GlaxoSmithKline plc 95
Tekmira Pharmaceuticals Corp. 96
Genentech, Inc. 97
Biotest AG 98
AbGenomics International, Inc. 99
Oxford BioMedica plc 100
Infinity Pharmaceuticals, Inc. 101
YM BioSciences Inc. 102
FibroGen, Inc. 103
Light Sciences Oncology, Inc. 104
Piramal Healthcare Limited 105
MediGene AG 106
Prolexys Pharmaceuticals, Inc. 107
BioSante Pharmaceuticals, Inc. 108
ZIOPHARM Oncology, Inc. 109
Novartis AG 110
Samyang Corporation 111
Aphios Corporation 112
Astellas Pharma Inc. 113
SuperGen, Inc. 114
Taiho Pharmaceutical Co., Ltd. 115
Yakult Honsha Co., Ltd. 116
Zeria Pharmaceutical Co Ltd 117
Exelixis, Inc. 118
Aduro BioTech 119
Incyte Corporation 120
Merck KGaA 121
Advaxis, Inc. 122
Neogenix Oncology Corporation 123
EntreMed, Inc. 124
Anavex Life Sciences Corp. 125
ValiRx Plc 126
ImmunoCellular Therapeutics, Ltd. 127
IMMUNOMEDICS, INC 128
Lorus Therapeutics Inc 129
Marshall Edwards, Inc. 130
MethylGene Inc 131
Molecular Insight Pharmaceuticals, Inc. 132
Northwest Biotherapeutics, Inc. 133
Oncolytics Biotech Inc. 134
Patrys Limited 135
Peregrine Pharmaceuticals, Inc. 136
Critical Outcome Technologies Inc. 137
La Jolla Pharmaceutical Company 138
Bionovo, Inc. 139
Telik, Inc. 140
Champions Biotechnology, Inc. 141
Oncogenex Pharmaceuticals, Inc. 142
Pharmacyclics, Inc. 143
ProMetic Life Sciences Inc. 144
Green Cross Corporation 145
Innocell Corporation 146
OncoTherapy Science, Inc. 147
Quest PharmaTech Inc. 148
Threshold Pharmaceuticals, Inc. 149
Natco Pharma Limited 150
Rexahn Pharmaceuticals, Inc. 151
MabVax Therapeutics, Inc. 152
Morphotek, Inc. 153
Antisense Pharma GmbH 154
Avanti Therapeutics 155
Wilex AG 156
GANYMED Pharmaceuticals AG 157
Philogen S.p.A. 158
Multimmune GmbH 159
Nerviano Medical Sciences S.r.l. 160
Wellstat Therapeutics Corporation 161
Hutchison MediPharma Limited 162
ERYtech Pharma 163
Advantagene, Inc. 164
Alethia Biotherapeutics Inc. 165
Ascenta Therapeutics, Inc. 166
Gene Signal International SA. 167
Heat Biologics, Inc. 168
MacroGenics, Inc. 169
Antyra, Inc. 170
OncoMed Pharmaceuticals, Inc. 171
TetraLogic Pharmaceuticals 172
Celecure AS 173
Azaya Therapeutics, Inc. 174
Merrimack Pharmaceuticals, Inc. 175
RESprotect GmbH 176
ProNAi Therapeutics, Inc. 177
Jennerex Biotherapeutics, Inc. 178
Stemline Therapeutics, Inc. 179
Axcentua Pharmaceuticals AB 180
BioCancell Therapeutics, Inc. 181
Cornerstone Pharmaceuticals, Inc. 182
Pharminox Limited 183
PhytoCeutica, Inc. 184
KangLaiTe USA 185
NovaLead Pharma Pvt. Ltd. 186
Esperance Pharmaceuticals, Inc. 187
Omeros Corporation 188
Transtech Pharma, Inc. 189
Welichem Biotech Inc. 190
Oncolys BioPharma Inc. 191
Globeimmune, Inc. 192
NewLink Genetics Corporation 193
Tragara Pharmaceuticals, Inc. 194
Cellceutix Corporation 195
PharmaMar, S.A. 196
CG Therapeutics, Inc. 197
Quintessence Biosciences, Inc. 198
AB Science 199
Tigris Pharmaceuticals, Inc. 200
Genelux Corporation 201
Lipopharma 202
Nereus Pharmaceuticals, Inc. 203
Medisyn Technologies, Inc. 204
Keystone Nano, Inc. 205
Perseus Proteomics, Inc. 206
Pique Therapeutics 207
Cancer Therapeutics CRC Pty Ltd 208
Targa Therapeutics Corp. 209
NuCana BioMed Limited 210
KAEL-GemVax 211
Nuvilex, Inc. 212
iCeutica, Inc. 213
Mebiopharm Co., Ltd. 214
Polaris Group 215
DEKK-TEC, Inc. 216
IkerChem S.L. 217
Regulon Inc. 218
TAU Therapeutics, LLC 219
Gradalis Inc. 220
Epeius Biotechnologies Corporation 221
CytomX, LLC. 222
Pancreatic Cancer – Therapeutics Assessment 223
Assessment by Monotherapy Products 223
Assessment by Combination Products 224
Assessment by Route of Administration 225
Assessment by Molecule Type 227
Drug Profiles 230
yttrium Radiotherapy - Drug Profile 230
GV-1001 - Drug Profile 232
HyperAcute Pancreas Immunotherapy - Drug Profile 234
Rexin-G - Drug Profile 235
gemcitabine - Drug Profile 237
Gemcitabine + Nab-Paclitaxel1 - Drug Profile 238
Capecitabine + Gemcitabine - Drug Profile 239
Gemcitabine Hydrochloride + Fluorouracil + Radiation Therapy - Drug Profile 241
Gemcitabine + Capecitabine + Radiation Therapy - Drug Profile 243
Erlotinib + Gemcitabine - Drug Profile 245
masitinib - Drug Profile 247
gemcitabine - Drug Profile 249
Capecitabine + Fluorouracil + Gemcitabine - Drug Profile 250
Gemcitabine + TS-1 - Drug Profile 252
5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile 254
nimotuzumab - Drug Profile 255
Gemcitabine + Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 257
gemcitabine - Drug Profile 258
S-1 + Oxaliplatin - Drug Profile 259
OTS-102 + Gemcitabine - Drug Profile 261
SmofKabiven + 5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile 262
gemcitabine - Drug Profile 264
Gemcitabine + Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 265
gemcitabine - Drug Profile 267
Omegaven + 5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile 268
Frekavit Fat-Soluble + 5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile 270
Frekavit Water-Soluble Novum + 5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile 272
Tracitrans Plus + 5-Fluorouracil + Folinic acid + Oxaliplatin - Drug Profile 274
Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 276
gemcitabine - Drug Profile 277
tegafur + gimeracil + oteracil potassium - Drug Profile 278
cisplatin - Drug Profile 279
uridine triacetate - Drug Profile 281
Gemcitabine Hydrochloride + Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 283
gemcitabine - Drug Profile 284
tegafur - Drug Profile 285
Gemcitabine + Oxaliplatin - Drug Profile 286
Gemcitabine + Human Epidermal Growth Factor Receptor Type I - Drug Profile 287
Pancreatic Cancer Therapeutics – Drug Profile Updates 288
Pancreatic Cancer Therapeutics – Discontinued Products 296
Pancreatic Cancer Therapeutics - Dormant Products 302
Pancreatic Cancer – Product Development Milestones 327
Featured News & Press Releases 327
Appendix 336
Methodology 336
Coverage 336
Secondary Research 336
Primary Research 336
Expert Panel Validation 336
Contact Us 337
Disclaimer 337

List of Tables
Number of Products Under Development for Pancreatic Cancer, H2 2012 18
Products under Development for Pancreatic Cancer – Comparative Analysis, H2 2012 19
Number of Products under Development by Companies, H2 2012 21
Number of Products under Development by Companies, H2 2012 (Contd..1) 22
Number of Products under Development by Companies, H2 2012 (Contd..2) 23
Number of Products under Development by Companies, H2 2012 (Contd..3) 24
Number of Products under Development by Companies, H2 2012 (Contd..4) 25
Number of Products under Development by Companies, H2 2012 (Contd..5) 26
Number of Products under Development by Companies, H2 2012 (Contd..6) 27
Number of Products under Development by Companies, H2 2012 (Contd..7) 28
Number of Products under Development by Companies, H2 2012 (Contd..8) 29
Number of Products under Development by Companies, H2 2012 (Contd..9) 30
Number of Products under Development by Companies, H2 2012 (Contd..10) 31
Number of Products under Development by Companies, H2 2012 (Contd..11) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 45
Comparative Analysis by Late Stage Development, H2 2012 46
Comparative Analysis by Mid Clinical Stage Development, H2 2012 47
Comparative Analysis by Early Clinical Stage Development, H2 2012 48
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 49
Products under Development by Companies, H2 2012 50
Products under Development by Companies, H2 2012 (Contd..1) 51
Products under Development by Companies, H2 2012 (Contd..2) 52
Products under Development by Companies, H2 2012 (Contd..3) 53
Products under Development by Companies, H2 2012 (Contd..4) 54
Products under Development by Companies, H2 2012 (Contd..5) 55
Products under Development by Companies, H2 2012 (Contd..6) 56
Products under Development by Companies, H2 2012 (Contd..7) 57
Products under Development by Companies, H2 2012 (Contd..8) 58
Products under Development by Companies, H2 2012 (Contd..9) 59
Products under Development by Companies, H2 2012 (Contd..10) 60
Products under Development by Companies, H2 2012 (Contd..11) 61
Products under Development by Companies, H2 2012 (Contd..12) 62
Products under Development by Companies, H2 2012 (Contd..13) 63
Products under Development by Companies, H2 2012 (Contd..14) 64
Products under Development by Companies, H2 2012 (Contd..15) 65
Products under Investigation by Universities/Institutes, H2 2012 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 89
Bristol-Myers Squibb Company, H2 2012 90
Johnson & Johnson, H2 2012 91
F. Hoffmann-La Roche Ltd., H2 2012 92
Amgen Inc., H2 2012 93
Sanofi-Aventis, H2 2012 94
AstraZeneca PLC, H2 2012 95
Eli Lilly and Company, H2 2012 96
Viralytics Ltd., H2 2012 97
GlaxoSmithKline plc, H2 2012 98
Tekmira Pharmaceuticals Corp., H2 2012 99
Genentech, Inc., H2 2012 100
Biotest AG, H2 2012 101
AbGenomics International, Inc., H2 2012 102
Oxford BioMedica plc, H2 2012 103
Infinity Pharmaceuticals, Inc., H2 2012 104
YM BioSciences Inc., H2 2012 105
FibroGen, Inc., H2 2012 106
Light Sciences Oncology, Inc., H2 2012 107
Piramal Healthcare Limited, H2 2012 108
MediGene AG, H2 2012 109
Prolexys Pharmaceuticals, Inc., H2 2012 110
BioSante Pharmaceuticals, Inc., H2 2012 111
ZIOPHARM Oncology, Inc., H2 2012 112
Novartis AG, H2 2012 113
Samyang Corporation, H2 2012 114
Aphios Corporation, H2 2012 115
Astellas Pharma Inc., H2 2012 116
SuperGen, Inc., H2 2012 117
Taiho Pharmaceutical Co., Ltd., H2 2012 118
Yakult Honsha Co., Ltd., H2 2012 119
Zeria Pharmaceutical Co Ltd, H2 2012 120
Exelixis, Inc., H2 2012 121
Aduro BioTech, H2 2012 122
Incyte Corporation, H2 2012 123
Merck KGaA, H2 2012 124
Advaxis, Inc., H2 2012 125
Neogenix Oncology Corporation, H2 2012 126
EntreMed, Inc., H2 2012 127
Anavex Life Sciences Corp., H2 2012 128
ValiRx Plc, H2 2012 129
ImmunoCellular Therapeutics, Ltd., H2 2012 130
IMMUNOMEDICS, INC, H2 2012 131
Lorus Therapeutics Inc, H2 2012 132
Marshall Edwards, Inc., H2 2012 133
MethylGene Inc, H2 2012 134
Molecular Insight Pharmaceuticals, Inc., H2 2012 135
Northwest Biotherapeutics, Inc., H2 2012 136
Oncolytics Biotech Inc., H2 2012 137
Patrys Limited, H2 2012 138
Peregrine Pharmaceuticals, Inc., H2 2012 139
Critical Outcome Technologies Inc., H2 2012 140
La Jolla Pharmaceutical Company, H2 2012 141
Bionovo, Inc., H2 2012 142
Telik, Inc., H2 2012 143
Champions Biotechnology, Inc., H2 2012 144
Oncogenex Pharmaceuticals, Inc., H2 2012 145
Pharmacyclics, Inc., H2 2012 146
ProMetic Life Sciences Inc., H2 2012 147
Green Cross Corporation, H2 2012 148
Innocell Corporation, H2 2012 149

List of Figures
Number of Products under Development for Pancreatic Cancer, H2 2012 18
Products under Development for Pancreatic Cancer – Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 33
Late Stage Products, H2 2012 46
Mid Clinical Stage Products, H2 2012 47
Early Clinical Stage Products, H2 2012 48
Discovery and Pre-Clinical Stage Products, H2 2012 49
Assessment by Monotherapy Products, H2 2012 226
Assessment by Combination Products, H2 2012 227
Assessment by Route of Administration, H2 2012 228
Assessment by Stage and Route of Administration, H2 2012 229
Assessment by Molecule Type, H2 2012 230
Assessment by Stage and Molecule Type, H2 2012 231

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos